French immunotherapy specialist Neovacs raises 6€m from three US institutional investors. The private placement involves the issuance of more than 9 million shares.
Johnson & Johnson has entered a new deal with Danish biotech Bavarian Nordic worth up to US$879m to develop vaccine regimens against hepatitis B and HIV.
UK’s biggest pharma firm announced it will save an additional £1bn each year by 2020. 80% of the pharmaceutical R&D pipeline expenses will be directed towards two current (Respiratory and HIV/infectious diseases) and two potential (Oncology and Immuno-inflammation) priority areas.
French yeast manufacturer Lesaffre acquires an equity stake in US biotech company Intralytix. Paying more than €15m, Lesaffre gains valuable insights into the development and commercialisation of bacteriophage-based products.
Swiss-based pharmaceutical company Myovant Sciences Ltd. is adding four new executives. Among them is a new Chief Medical Director, Juan Camilo Arjona Ferreira. In addition, the company increases its competence in regulatory affairs.
French Antabio receives funding by the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). Including future milestone payments, Antabio is eligible for up to €7.6m for their treatment of chronic infections in cystic fibrosis patients.
British pharma company GlaxoSmithKline plc. is expanding its company board and announced Laurie Glimcher as a non-executive director. Glimcher will join the board on 1 September.
French vaccines expert Valneva SE announced that the FDA has granted Fast Track designation for its Lyme borreliosis vaccine candidate VLA15.
Spanish Capital Cell was one of the first equity crowdfunding platforms that specialised in life sciences and biotech projects in Europe. In March, the group raised more than €1m through funding through the Spanish biotech campaign Bionure a new record. EuroBiotech talked to Capital Cell founder Daniel Oliver about their recent expansion into the UK and the development of the European life sciences crowdfunding scene.
After 3 years of collaboration Roche has ended a cancer deal with the Spanish biotech company Oryzon granting the rights to their cancer candidate ORY-1001.